Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Does Next Generation Sequencing (NGS)-Based CYP2D6 Sequencing Improve Genotype-Phenotype Concordance in Tamoxifen-Treated Patients?

Clinical pharmacology and therapeutics·2026
Same author

Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics.

Cancer chemotherapy and pharmacology·2026
Same author

Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. <i>Cancers</i> 2026, <i>18</i>, 124.

Cancers·2026
Same author

A multi-ancestry genome-wide study of tamoxifen metabolism and breast cancer recurrence.

NPJ breast cancer·2026
Same author

Model-Informed Precision Dosing of Protein Kinase Inhibitors: Evaluation of Model-Averaging and Flattened Priors Methods.

Clinical pharmacokinetics·2026
Same author

Correction: Exposure-response relationship of cabozantinib in patients with metastatic renal cell carcinoma treated in routine care.

British journal of cancer·2026
Same journal

Glucagon-Like Peptide-1 Receptor Agonists in Cocaine Use Disorder: Clinical Observations and Underlying Mechanisms.

Fundamental & clinical pharmacology·2026
Same journal

TAAR1-Associated Trace Amines for Cutaneous Nociceptive Blockade in Rats.

Fundamental & clinical pharmacology·2026
Same journal

Synergistic Cardioprotection of Colchicine and Hyperbaric Oxygen Therapy in a Rat Model of Remote Ischemia-Reperfusion Injury.

Fundamental & clinical pharmacology·2026
Same journal

Probucol Exerts Anticancer Effects on SW480 Human Colorectal Cancer Cells via Modulation of Apoptosis- and Angiogenesis-Related Proteins.

Fundamental & clinical pharmacology·2026
Same journal

Nebivolol Protects the Thoracic and Abdominal Aorta and Their Perivascular Adipose Tissue From the Differential Detrimental Effects of Obesity.

Fundamental & clinical pharmacology·2026
Same journal

Monitoring of Clinics That Use Direct-to-Consumer Advertising for Off-Label Ketamine in the New York Metropolitan Area: A Cross-Sectional Systematic Web Search.

Fundamental & clinical pharmacology·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2026

Assessment of Child Anthropometry in a Large Epidemiologic Study
09:36

Assessment of Child Anthropometry in a Large Epidemiologic Study

Published on: February 2, 2017

Population approaches in paediatrics.

Etienne Chatelut1

  • 1Institut Claudius-Regaud, EA3035 Université de Toulouse, F-31052 Toulouse cedex, France. chatelut.etienne@claudiusregaud.fr

Fundamental & Clinical Pharmacology
|December 4, 2008
PubMed
Summary
This summary is machine-generated.

Population pharmacokinetic (PK) studies are essential for pediatric drug development, offering a robust method for evaluating new medicines in children. This approach, mandated by EU legislation, adapts standard PK methods to account for pediatric-specific factors.

More Related Videos

Adult and Pediatric Porcine Model of Acute Volume Overload
06:09

Adult and Pediatric Porcine Model of Acute Volume Overload

Published on: January 12, 2024

Related Experiment Videos

Last Updated: Jun 27, 2026

Assessment of Child Anthropometry in a Large Epidemiologic Study
09:36

Assessment of Child Anthropometry in a Large Epidemiologic Study

Published on: February 2, 2017

Adult and Pediatric Porcine Model of Acute Volume Overload
06:09

Adult and Pediatric Porcine Model of Acute Volume Overload

Published on: January 12, 2024

Area of Science:

  • Pharmacology
  • Clinical Pharmacology
  • Pediatric Drug Development

Background:

  • Population pharmacokinetic (PK) analysis is increasingly vital in drug development.
  • New European Union legislation mandates pediatric drug evaluation.
  • Population PK is a key strategy for assessing medicines in pediatric populations.

Purpose of the Study:

  • Compare standard PK with population PK methods.
  • Highlight the suitability of population PK for pediatric studies.
  • Discuss pediatric-specific covariates and provide PK/PK-PD study examples.

Main Methods:

  • Comparative analysis of standard PK and population PK methodologies.
  • Identification and presentation of pediatric patient characteristics (covariates).
  • Review of published pediatric population PK and PK-pharmacodynamic (PK-PD) studies.

Main Results:

  • Population PK is better suited for pediatric drug development than standard PK.
  • Pediatric covariates significantly influence drug disposition.
  • Population PK studies are more prevalent than PK-PD studies in this field.

Conclusions:

  • Population PK is the preferred method for pediatric drug development, aligning with regulatory requirements.
  • Understanding pediatric covariates is crucial for optimizing drug therapy.
  • Further research integrating PK-PD modeling is needed to advance pediatric pharmacotherapy.